Authors: Simmons, Rita G.; Phillips, Jeffrey B.; Lojewski, Renee A.; Wang, Zuwei; Boyd, Jason L.; Putcha, Lakshmi

Source: Aviation, Space, and Environmental Medicine, Volume 81, Number 4, April 2010 , pp. 405-412(8)

Publisher: Aerospace Medical Association

Abstract:

Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med 2010; 81:405-12.

Introduction: Scopolamine is an effective motion sickness prophylactic, but oral and transdermal formulations are slowly absorbed. To enhance absorption and potentially efficacy, an intranasal formulation of scopolamine (INSCOP) was tested. Method: There were 16 motion sickness susceptible subjects with an average age of 23.5 ± 3.0 yr and an average score of 11.3 ± 4.7 on the Modified Motion Sickness Susceptibility Questionnaire-Short Form who volunteered to participate in the study. Each subject was given 0.4 mg of INSCOP and a placebo in a randomized, double-blind crossover design and, at 40 min post-dose, experienced Coriolis cross-coupling in a staircase progression until moderate nausea. Efficacy data and cognitive, physiological, and alertness assessments were collected during baseline control and throughout experimental testing. Results: Intranasal scopolamine significantly increased the mean number of head movements tolerated [INSCOP 275.9 ± 120.5, Placebo 230.7 ± 76.4; t (<xref ref-type="bibr" rid="bib15">15</xref>) = 2.21]. Estimation of medication absorption via plasma concentration indicated the drug was absorbed relatively rapidly to measurable levels by 15 min post-administration. Diastolic blood pressures and heart rate were significantly lower after administration of INSCOP compared to placebo. No significant cognitive or medication side effects were reported. Subjects reported no significant decrease in alertness as indicated by the Karolinska Sleepiness Scale. Conclusions: Results of the current study strongly suggest that intranasal scopolamine is efficacious for the treatment of motion sickness in susceptible individuals with no significant cognitive or sedative effects. Intranasal delivery offers a promising alternative for use in dynamic operational environments without cognitive detriment or increased side effects.

References: 18 references open in new window

Articles that cite this article?

Supplementary Data: 1 item

Keywords: motion sickness; Coriolis cross-coupling; clinical trials

Document Type: Research article

DOI: http://dx.doi.org/10.3357/ASEM.2668.2010

Publication date: 2010-04-01

More about this publication?

• The peer-reviewed monthly journal, Aviation, Space, and Environmental Medicine (ASEM) provides contact with physicians, life scientists, bioengineers, and medical specialists working in both basic medical research and in its clinical applications. It is the most used and cited journal in its field. ASEM is distributed to more than 80 nations.
• Information for Authors
• Subscribe to this Title
• Membership Information
• Information for Advertisers
• Submit Articles
• 2011 Annual Meeting and Event Information
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Transportation ,  Medicine (General) ,  Public Health
• By this author: Simmons, Rita G. ;  Phillips, Jeffrey B. ;  Lojewski, Renee A. ;  Wang, Zuwei ;  Boyd, Jason L. ;  Putcha, Lakshmi

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers